RxDoctor Payments Data

Gregory Ganzer, DO

Dermatology · Wheeling, WVNPI 1326163890

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 39.1% of the total. Reporting peaked in 2019 at $128 and has fallen 52.3% since, to $61 in 2025. That places this record below the midpoint for dermatology clinicians in WV, where the typical reported total is $2,210.

$217in general payments, 2019–2025

Across 14 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$85
  • Amgen$53
  • Johnson & Johnson$17
  • Pfizer$15
  • LEO Pharma Inc.$14
  • Novartis$13
  • plus $20 from 2 others

What the payments were for

  • Food & beverage$20293%
  • Education$157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$217 in reported general payments places this provider in the 10th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$9,592
Medicare patients
48
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast51$240,509
Humira PenAdalimumab15$107,613
Dupixent PenDupilumab24$87,887
Clobetasol Propionate76$2,802
Triamcinolone Acetonide247$2,716
Tacrolimus13$2,032
Ketoconazole143$1,701
Betamethasone Dipropionate46$1,652
Clindamycin Phosphate43$1,591
Fluorouracil21$1,525
Doxycycline Hyclate93$1,440
Metronidazole32$1,361
CiclopiroxCiclopirox Olamine56$1,345
Mupirocin113$671
Halobetasol Propionate17$495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$53$240,50951 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 39 dermatology providers in West Virginia.

Other dermatology in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →